Novo NordiskSee all their emails

Novo’s Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis

A real announcement email from Novo Nordisk. Captured September 29, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

Novo’s Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis email from Novo Nordisk screenshot

Captured Announcement

Novo Nordisk press release announcing new real-world clinical study results regarding Ozempic cardiovascular outcomes.

Top corporate logo followed by a plain, text-heavy layout structured like an official press release, featuring headline, bullet points, multiple body paragraphs, contact information tables, and a legal footer.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.